Crizotinib
Back to searchMolecule Structure
Scientific Name
Crizotinib
Description of the Drug
Crizotinib is a receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08865
http://www.drugbank.ca/drugs/DB08865
Brand Name(s)
Xalkori
Company Owner(s)
Pf Prism Cv
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | CHIMERIC PROTEIN | INHIBITOR | CHEMBL2111387 |
| Hepatocyte growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL3717 |
| EML4-ALK | CHIMERIC PROTEIN | INHIBITOR | CHEMBL3883330 |
| ALK tyrosine kinase receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL4247 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL93829 | |
| PharmGKB | PA165946122 | |
| DrugBank | DB08865 | |
| PubChem: Thomson Pharma | 16729581 | |
| PubChem | 11626560 | |
| LINCS | LSM-1027 | |
| Nikkaji | J2.735.431I | |
| PDBe | VGH | |
| BindingDB | 50306682 | |
| DrugCentral | 4187 | |
| Brenda | 213556 | 62615 |
| Guide to Pharmacology | 4903 | |
| rxnorm | CRIZOTINIB | XALKORI |
| PubChem: Drugs of the Future | 125299329 | |
| ChEBI | 64310 | |
| ZINC | ZINC000035902489 |
